Doug made a passing comment to the effect of redeploying efforts (into US FDA application?) as a reason for the sales. If I heard correctly, this would pass the sniff test IMO given the ~60% headcount reduction they mentioned as part of the restructure, and that perhaps without US sales, Febridx top line may not stack up to carry business forward.
Hoping someone can confirm or correct what I heard?
AIMHO. DYOR.
Ann: FY23 Full Year Results Announcement, page-33
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
